Drug treatment effects on disease progression

被引:113
作者
Chan, PLS [1 ]
Holford, NHG [1 ]
机构
[1] Univ Auckland, Sch Med, Div Pharmacol & Clin Pharmacol, Auckland 1030, New Zealand
关键词
disease progress models; symptomatic; protective; Alzheimer's; Parkinson's; osteoporosis;
D O I
10.1146/annurev.pharmtox.41.1.625
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Degenerative diseases are characterized by a worsening of disease status over time. The rate of deterioration is determined by the natural rate of progression of the disease and by the effect of drug treatments. A goal of drug treatment is to slow disease progression. Drug treatments can be categorized as symptomatic or protective. Symptomatic treatments do not affect the rate of disease progression whereas protective treatments have the ability to slow disease progression down. Many current methods for describing disease progression have two common drawbacks: a linear relationship between time and disease status is assumed, and within- and between-subject variability is ignored. Disease progress models combined with pharmacokinetic-pharmacodynamic models and hierarchical random effects statistical models provide insights into understanding the time course and management of degenerative disease.
引用
收藏
页码:625 / 659
页数:35
相关论文
共 148 条
  • [1] ALAVI A, 1993, J NUCL MED, V34, P1681
  • [2] ALI WA, 2000, J BIOPHARM STAT, V10, P165
  • [3] EFFECTS OF SMOKING INTERVENTION AND THE USE OF AN INHALED ANTICHOLINERGIC BRONCHODILATOR ON THE RATE OF DECLINE OF FEV(1) - THE LUNG HEALTH STUDY
    ANTHONISEN, NR
    CONNETT, JE
    KILEY, JP
    ALTOSE, MD
    BAILEY, WC
    BUIST, AS
    CONWAY, WA
    ENRIGHT, PL
    KANNER, RE
    OHARA, P
    OWENS, GR
    SCANLON, PD
    TASHKIN, DP
    WISE, RA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (19): : 1497 - 1505
  • [5] Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
    Bakris, GL
    Copley, JB
    Vicknair, N
    Sadler, R
    Leurgans, S
    [J]. KIDNEY INTERNATIONAL, 1996, 50 (05) : 1641 - 1650
  • [6] MEASUREMENT OF HUMAN CEREBRAL MONOAMINE-OXIDASE TYPE-B (MAO-B) ACTIVITY WITH POSITRON EMISSION TOMOGRAPHY (PET) - A DOSE RANGING STUDY WITH THE REVERSIBLE INHIBITOR RO-19-6327
    BENCH, CJ
    PRICE, GW
    LAMMERTSMA, AA
    CREMER, JC
    LUTHRA, SK
    TURTON, D
    DOLAN, RJ
    KETTLER, R
    DINGEMANSE, J
    DAPRADA, M
    BIZIERE, K
    MCCLELLAND, GR
    JAMIESON, VL
    WOOD, ND
    FRACKOWIAK, RSJ
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (02) : 169 - 173
  • [7] MILD SENILE DEMENTIA OF THE ALZHEIMER TYPE .2. LONGITUDINAL ASSESSMENT
    BERG, L
    MILLER, JP
    STORANDT, M
    DUCHEK, J
    MORRIS, JC
    RUBIN, EH
    BURKE, WJ
    COBEN, LA
    [J]. ANNALS OF NEUROLOGY, 1988, 23 (05) : 477 - 484
  • [8] POSITRON EMISSION TOMOGRAPHY SUGGESTS THAT THE RATE OF PROGRESSION OF IDIOPATHIC PARKINSONISM IS SLOW
    BHATT, MH
    SNOW, BJ
    MARTIN, WRW
    PATE, BD
    CALNE, DB
    [J]. ANNALS OF NEUROLOGY, 1991, 29 (06) : 673 - 677
  • [9] RENAL PROTECTIVE EFFECT OF ENALAPRIL IN DIABETIC NEPHROPATHY
    BJORCK, S
    MULEC, H
    JOHNSEN, SA
    NORDEN, G
    AURELL, M
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6823): : 339 - 343
  • [10] BOECKMANN AJ, 1992, NONMEM USERS GUIDES